This is a StreetInsider.com Premium Only Page

(SRRA) – Company Press Releases

Jul 18, 2022 04:05 PM Codexis Announces CEO Transition Effective August 9, 2022

Jun 17, 2022 07:00 AM Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

May 26, 2022 05:00 PM Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting

May 12, 2022 10:00 AM Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

May 6, 2022 07:00 AM Sierra Oncology Reports First Quarter 2022 Results

May 5, 2022 04:05 PM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Apr 25, 2022 08:00 AM RayzeBio Appoints Angie You, Ph.D., to its Board of Directors

Apr 13, 2022 12:13 PM SIERRA ONCOLOGY ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of SRRA and Encourages Investors to Contact the Firm

Apr 13, 2022 02:05 AM GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn

Apr 6, 2022 06:00 PM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Mar 11, 2022 07:00 AM Sierra Oncology to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Mar 10, 2022 07:00 AM Sierra Oncology Reports 2021 Year End Results

Mar 4, 2022 04:05 PM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Feb 22, 2022 08:00 AM Frazier Life Sciences Adds Highly Experienced Biopharmaceutical Executive to Team

Feb 18, 2022 04:05 PM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Feb 4, 2022 04:05 PM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Feb 3, 2022 04:05 PM Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Feb 3, 2022 07:00 AM Sierra Oncology to Participate in Guggenheim Oncology Conference

Jan 31, 2022 04:05 PM Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities

Jan 27, 2022 07:00 AM Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference

Jan 26, 2022 11:05 PM Sierra Oncology Announces Pricing of Upsized Public Offering of Securities

Jan 25, 2022 04:01 PM Sierra Oncology Announces Proposed Public Offering of Common Stock

Jan 25, 2022 07:00 AM Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib

Jan 25, 2022 07:00 AM Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis

Jan 19, 2022 12:00 PM Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients

Jan 18, 2022 07:00 AM Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis

Jan 7, 2022 04:05 PM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 5, 2022 07:00 AM Sierra Oncology to Present at HC Wainwright BioConnect Conference

Dec 13, 2021 06:34 PM Sierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response in Myelofibrosis Patients

Dec 6, 2021 07:00 AM Sierra Oncology Announces Investor Event to Review MOMENTUM Trial Design and Available Phase 3 Momelotinib Data in Myelofibrosis

Dec 3, 2021 04:05 PM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov 12, 2021 07:00 AM Sierra Oncology Announces Presentation at Jefferies London Healthcare Conference

Nov 10, 2021 04:15 PM ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors

Nov 10, 2021 04:15 PM ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors

Nov 5, 2021 07:00 AM Sierra Oncology Reports Third Quarter 2021 Results

Nov 4, 2021 09:00 AM Sierra Oncology Announces Momelotinib Poster Accepted for Presentation at ASH

Nov 3, 2021 04:05 PM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Oct 4, 2021 04:14 PM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sep 7, 2021 07:00 AM Sierra Oncology to Present at Three September Investor Conferences

Sep 3, 2021 04:05 PM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aug 9, 2021 07:00 AM Sierra Oncology Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding

Aug 5, 2021 04:10 PM  Sierra Oncology Reports Second Quarter 2021 Results

Aug 5, 2021 04:05 PM  Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline

Aug 5, 2021 07:00 AM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jul 22, 2021 07:00 AM Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jul 7, 2021 07:00 AM Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jun 23, 2021 07:00 AM Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jun 21, 2021 07:00 AM Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial

Jun 14, 2021 07:00 AM Sierra Oncology Hosting KOL Panel Event to Discuss Momelotinib Data Presented at EHA 2021

Jun 11, 2021 03:00 AM Momelotinib Oral Presentation at European Hematology Association Demonstrates Association Between Transfusion Independence and Improved Overall Survival